Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (ELAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01078610|
Recruitment Status : Withdrawn (Study stopped prior to enrollment.)
First Posted : March 2, 2010
Last Update Posted : August 10, 2012
|Condition or disease||Intervention/treatment|
|Psoriatic Arthritis||Biological: adalimumab (Humira)|
The primary objective of the Non-Interventional Study is to explore the therapeutic success, measured by improvements in the following target variables (with regard to the respective baseline value):
- The number of missed working days
- The self-assessed workability
- The severity of clinical symptoms (number of tender and swollen joints, C-reactive Protein and erythrocyte sedimentation rate respectively; total score Disease Activity Score 28, Psoriasis Area and Severity Index)
- The severity of functional impairment (Health Assessment Questionnaire)
- The health-related quality of life .
All of the patient and disease characteristics which are documented at baseline will be evaluated for their additional impact on the target variables (therapeutic success). Particularly the impact of previous biologic therapies on clinical target variables will be evaluated.
The secondary objective is to document the therapeutic success by the following variables:
- The number of physician visit
- The number and duration of hospitalization
- The number of days of impairment in non-occupational activities
- Pain, exhaustion/fatigue
- The reduction of number and dose of concomitant medication
- Patient's assessment of adalimumab therapy compared to previous therapies.
Target parameters for safety evaluation of adalimumab are:
- The evaluation of safety and tolerability by the documentation and analysis of serious adverse events (SAEs) and adverse events (AEs)
- Evaluation of safety and tolerability for subgroups of patients with common frequent concomitant diseases, especially diabetes type II, cardiovascular, liver, and renal insufficiencies, and related concomitant medications.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice|
U.S. FDA Resources
|Psoriatic arthritis patients||
Biological: adalimumab (Humira)
40 mg adalimumab (Humira) every other week.
- Improvement in: number of missed working days, self-assessed workability, severity of clinical symptoms and functional impairment, health-related quality of life; safety an tolerability: documentation of adverse events and serious adverse events [ Time Frame: Months 0, 3, 6, 12, 24, 36, 48, 60 ]
- Number and duration of hospitalization; reduction of number and dose of concomitant medication: patient's assessment of adalimumab therapy compared to previous therapies. [ Time Frame: Months 0, 3, 6, 12, 24, 36, 48, 60 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078610
|Study Director:||Stefan Simianer, MD||Abbott Germany, Medical Department|